Medivation, Inc. (MDVN) is a pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MDVN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Medivation could be a solid choice for investors.
Current Quarter Estimates for MDVN
In the past 30 days, 6 estimates have gone higher for Medivation while no revision going lower in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 7 cents a share 30 days ago, to a profit of 27 cents today.
Current Year Estimates for MDVN
Meanwhile, Medivation’s current year figures are also looking quite promising, with 7 estimates moving higher in the past month, compared to 1 lower. The consensus estimate trend has also seen a boost for this time frame, increasing 75 cents per share 30 days ago to $1.38 per share today, an increase of 84.0%.
The stock has also started to move higher lately, adding 17.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
MEDIVATION INC (MDVN): Free Stock Analysis Report
Zacks Investment Research